The FDA granted Zepto Life Technology a Breakthrough Device designation for its FungiFlex Mold Panel, a plasma-based liquid biopsy intended to detect invasive mold infections by analyzing circulating cell-free DNA. The panel is designed to identify clinically relevant molds, including Aspergillus, Mucorales, Fusarium, and Scedosporium/Lomentospora. Zepto Life currently offers the test as a laboratory-developed test through its CLIA lab in St. Paul, Minnesota. The company argues that direct-from-blood cfDNA testing could shorten time to organism identification, a common bottleneck in managing invasive fungal disease where clinicians often must make treatment decisions before precise diagnosis. The Breakthrough Device designation adds regulatory acceleration potential for a direct pathogen detection approach that is positioned as complementary to imaging, microbiology, histopathology, and serology. Industry relevance is high because fungal diagnostics remain an area with significant unmet needs, and liquid biopsy workflows may expand the speed and specificity of early targeting of antifungal therapy.